Inozyme Pharma, Inc. (INZY)
Largest Insider Buys in Sector
INZY Stock Price History Chart
INZY Stock Performance
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is …
Insider Activity of Inozyme Pharma, Inc.
Over the last 12 months, insiders at Inozyme Pharma, Inc. have bought $0 and sold $52,210 worth of Inozyme Pharma, Inc. stock.
On average, over the past 5 years, insiders at Inozyme Pharma, Inc. have bought $48.08M and sold $3.96M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 833,333 shares for transaction amount of $4M was made by Pivotal bioVenture Partners Fund I, L.P. (director) on 2023‑08‑01.
List of Insider Buy and Sell Transactions, Inozyme Pharma, Inc.
| 2024-04-02 | Sale | CEO | 7,523 0.0122% | $6.94 | $52,210 | -30.35% | ||
| 2023-08-01 | director | 833,333 1.4418% | $4.80 | $4M | -7.57% | |||
| 2023-08-01 | director | 833,333 1.4418% | $4.80 | $4M | -7.57% | |||
| 2023-05-12 | director | 228,702 0.5377% | $6.25 | $1.43M | -20.56% | |||
| 2023-05-11 | director | 219,230 0.5045% | $6.48 | $1.42M | -24.92% | |||
| 2023-03-29 | director | 344,592 0.761% | $4.54 | $1.56M | +7.66% | |||
| 2023-03-28 | director | 156,766 0.3414% | $4.16 | $652,335 | +14.87% | |||
| 2023-03-27 | director | 51,074 0.1167% | $3.70 | $188,729 | +35.68% | |||
| 2022-12-15 | SVP, COO | 21,500 0.0569% | $1.39 | $29,885 | +205.94% | |||
| 2022-04-19 | 1.35M 2.811% | $3.69 | $5M | -33.04% | ||||
| 2022-04-19 | 1.07M 2.2197% | $3.69 | $3.95M | -33.04% | ||||
| 2022-04-19 | 1.07M 2.2197% | $3.69 | $3.95M | -33.04% | ||||
| 2022-04-19 | Chief Executive Officer | 67,750 0.1405% | $3.69 | $249,998 | -33.04% | |||
| 2022-04-19 | SVP, COO | 27,100 0.0562% | $3.69 | $99,999 | -33.04% | |||
| 2022-04-19 | SVP, CFO | 27,100 0.0562% | $3.69 | $99,999 | -33.04% | |||
| 2021-06-24 | Sale | Chief Executive Officer | 66,788 <0.0001% | $0.00 | $7 | -57.67% | ||
| 2021-01-28 | Sale | 10 percent owner | 375,000 1.469% | $21.00 | $7.88M | -30.07% | ||
| 2020-07-28 | 10 percent owner | 1.25M 6.0841% | $16.00 | $20M | +19.03% | |||
| 2020-07-28 | 10 percent owner | 375,000 1.8252% | $16.00 | $6M | +19.03% | |||
| 2020-07-28 | 10 percent owner | 250,000 1.2168% | $16.00 | $4M | +19.03% |
Insider Historical Profitability
| ENRIGHT PATRICK G | 4174379 6.4981% | $2.68 | 1 | 0 | <0.0001% | |
| Hopfner Robert Lorne | director | 2923110 4.5503% | $2.68 | 8 | 0 | <0.0001% |
| Pivotal bioVenture Partners Fund I, L.P. | director | 2923110 4.5503% | $2.68 | 2 | 0 | +19.03% |
| Longitude Capital Partners III, LLC | 10 percent owner | 2819379 4.3888% | $2.68 | 1 | 0 | +19.03% |
| Pivotal bioVenture Partners Fund I U.G.P., Ltd | 2661154 4.1425% | $2.68 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Adage Capital Partners Gp L L C | $40.82M | 8.62 | 5.33M | -3.77% | -$1.6M | 0.07 | |
| Pivotal Bioventure Partners Investment Advisor Llc | $34.43M | 7.27 | 4.49M | 0% | +$0 | 27.69 | |
| Sofinnova | $32.79M | 6.92 | 4.28M | 0% | +$0 | 0.07 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $28.2M | 5.95 | 3.68M | 0% | +$0 | 0.73 | |
| Eventide Asset Management | $24.36M | 5.14 | 3.18M | 0% | +$0 | 0.39 |